Anifrolumab(MEDI-546) is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).

ISRE:0.3 nM

Anifrolumab induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation at a concentration of 67.7 nM for 20 minutes[1].
Anifrolumab suppresses the differentiation of B cells into plasma cells at concentrations of 1 and 10 μg/mL for 6 or 7 days[1].
Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3 nM for the IFN-α subtypes, and 0.03 nM and 0.07 nM for IFN-β and IFN-ω, respectively[1].At a concentration of 67.7 nM, Anifrolumab dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production[1].

Human

Immobilized Human IFNAR1 Protein (Fc) at 2 μg/mL (30 μL/well) can bind Anifrolumab. The EC50 is 14.71 ng/mL.

Monoclonal

Unconjugated

DMSO: 60 mg/mL, Sonication is recommended.